Conclusion
METASTATIC BREAST CANCER
A subset of patients (10%) receiving trastuzumab in the metastatic setting have achieved long-term survival beyond 20 years.Long-term survival analyses of HER2-targeted therapies are lacking. This is a 20-year follow-up study of a phase II trial that evaluated the activity and safety of docetaxel in combination with carboplatin and trastuzumab in patients with HER2+ metastatic breast cancer.